FLASCO OncoPod

Florida Society of Clinical Oncology

Colorectal Cancer

Atypical Hemolytic Uremic Syndrome

HER2

Biliary Tract Cancer

Gastroesophageal Adenocarcinoma

Young Onset Colorectal Cancer

Oncology

HER2 Testing In GI Cancers

NGS

Metastatic Colorectal Cancer

EGFR Mutation In Lung Cancer

ASCO Edge

Endometrial Cancer

Chronic Lymphocytic Leukemia

IHC

Complement Inhibition

Oral Chemotherapy

Caregiver Support

Gastric Cancer

Multidisciplinary Team

The FLASCO OncoPod is a podcast series that brings you engaging interviews and conversations with oncology champions and thought leaders. Each episode explores important topics in cancer care, from the latest clinical advancements to FLASCO events and initiatives. Whether it’s discussing groundbreaking research, policy updates, or sharing personal stories from members, the OncoPod keeps oncology p... more

2 ratings

Publishes	Twice monthly	Episodes	26	Founded	2 years ago
Number of Listeners		Categories	Non-ProfitMedicineHealth & FitnessBusiness

Listen to this Podcast

Guests Hosts Charts Talking Points

Latest Episodes

CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors

The treatment landscape for chronic lymphocytic leukemia (CLL) has transformed dramatically over the past decade, creating new opportunities and new questions for clinicians managing this increasingly complex disease. In this episode of the FLASCO On... more

5 Jun 2026 • 27 min

What's New in Endometrial Cancer: Key Takeaways From SGO 2026

Join Scott E. Jordan, MD, FACOG, gynecologic oncologist at Broward Health, as he breaks down the most important endometrial cancer updates presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting.

In this episode, Dr. Jordan revie... more

2 Jun 2026 • 17 min

ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia

What does it take to successfully navigate the business of oncology while continuing to deliver exceptional patient care?

In this episode of the FLASCO OncoPod, Dr. Robin Zon joins Dr. Jorge Garcia for a thoughtful conversation about leadership, adv... more

11 May 2026 • 13 min

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls

In this final episode of the FLASCO OncoPod series, Drs. Jaglal, Fu, and Shahzad shift focus to the long-term management of atypical hemolytic uremic syndrome (aHUS) in oncology patients.

Building on the diagnostic and acute management discussions f... more

1 May 2026 • 7 min

Key Facts

Accepts Guests

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

MPN Pod: Stories from the MarrowBloodStream Media

Blood Cancer TalksRajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff

The Bloodline with Blood Cancer United PodcastBlood Cancer United

Recent Guests

Javier Pinilla-Ibarz

Hematologist at Moffitt Cancer Center, director of immunotherapy and lymphoma section

Moffitt Cancer Center

Episode: CLL Treatment Evolution: Rethinking Monotherapy vs Combination Strategies in the Era of Next-Generation BTK Inhibitors

Robin Zon

Former president of ASCO

ASCO

Episode: ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon ASCO Edge and the Future of Oncology Practice Leadership with Dr. Robin Zon & Dr. Jorge Garcia

Dr. Jaglal

Cardiothoracic/hematology specialist mentioned in the discussion

Cleveland Clinic

Episode: "How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions

Dr. Fu

Oncologist/hematologist involved in case discussion

Cleveland Clinic

Episode: "How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 2: Acute Management: TTP vs aHUS and Treatment Decisions

Noman Ashraf

Associate Professor of Medicine at the University of South Florida, Tampa General Cancer Institute

University of South Florida/Tampa General Hospital

Episode: Advancing Care in GI and Biliary Tract Cancers Series Episode 4: GEA Disease State and Patient Management; Importance of the MDT

Dr. Majeed

GI oncologist discussing HER2-directed therapy in GI cancers

Episode: Advancing Care in GI and Biliary Tract Cancers Series Episode 3: HER2 Agents in GI Cancers - Understanding Mechanisms of Action

Dr. Ashraf

GI oncologist contributing clinical insights on HER2-directed therapies

Episode: Advancing Care in GI and Biliary Tract Cancers Series Episode 3: HER2 Agents in GI Cancers - Understanding Mechanisms of Action

Dr. Patel

A clinician discussing HER2 testing in GI cancers, focusing on clinical implications and practice patterns.

Episode: Advancing Care in GI and Biliary Tract Cancers Series Episode 2: HER2 Testing in BTC and GEA

Dr. Ghayouri

Pathology expert addressing HER2 testing guidelines, tissue requirements, and interpretation in GI cancers.

Moffitt Cancer Center

Episode: Advancing Care in GI and Biliary Tract Cancers Series Episode 2: HER2 Testing in BTC and GEA

Hosts

Edgardo Santos

Host of the FLASCO OncoPod

Tiago Bianchi

Host of the FLASCO OncoPod; Host of the episode

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts

#47

Colombia/Health & Fitness/Medicine

Talking Points

Recent interactions between the hosts and their guests.

Advancing Care in GI and Biliary Tract Cancers Series Episode 1: BTC Disease State and Patient Management; Importance of the MDT

Q: What is the standard first-line treatment for metastatic BTC and what factors guide this choice?

The standard first-line in metastatic BTC is chemoimmunotherapy with gemcitabine and cisplatin plus a PD-1/PD-L1 inhibitor, guided by targeted sequencing to identify actionable mutations and biomarker-driven considerations; treatment aims to control disease while considering tolerability.

Advancing Care in GI and Biliary Tract Cancers Series Episode 1: BTC Disease State and Patient Management; Importance of the MDT

Q: What does initial workup and staging look like for BTC?

Initial workup includes CT of the chest, MRI of the abdomen, possible PET imaging, and tissue confirmation via endoscopic procedures or imaging-guided biopsies, with emphasis on multidisciplinary collaboration and careful sampling to avoid compromising transplantation eligibility in certain cases.

Advancing Care in GI and Biliary Tract Cancers Series Episode 1: BTC Disease State and Patient Management; Importance of the MDT

Q: What are biliary tract cancers and how are they classified?

BTCs are a group of rare cancers that include intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer; classification is based on the anatomical location of the tumor, with ongoing refinements in imaging and pathology to improve accuracy and treatment planning.

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls

Q: If you really think it's drug-induced and you take out the drug, should you just stop, and is there data to guide duration?

There is limited data, but in non-pathogenic mutation scenarios with a drug trigger, stopping the drug can be appropriate; duration decisions should be individualized based on genetic findings, presence of inhibitors, and response to cessation.

"How I Treat" Micro-Learning Atypical HUS Triggered by Malignancy or Drug Exposure Part 3: Genetics, Duration of Therapy, and Real-World Pearls

Q: My question to both of you, like you will be doing the genetic testing on all the atypical HUS patients and how do you approach after the genetic testing?

The panel often confirms whether there is a pathogenic mutation or not; if non-pathogenic mutations are found and the clinical picture suggests a drug trigger, we may consider stopping the offending drug while continuing to monitor the patient closely, especially if there is clinical improvement and no inhibitor detected.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About FLASCO OncoPod

What is FLASCO OncoPod about and what kind of topics does it cover?

The show consistently centers on oncology and hematology topics with a bias toward practical, real-world applications in patient care. Episodes frequently feature clinicians and researchers sharing updates on treatment paradigms, biomarker-driven decision-making, and multidisciplinary care pathways across solid tumors and hematologic conditions. Notable throughlines include the evolution of targeted therapies (including BTK inhibitors and HER2-directed approaches), diagnostic testing and pathology guidelines, the role of multidisciplinary teams in complex cancers, and practical considerations for frontline sequencing, management of treatment-related toxicities, and patient support. A distinctive strength is the blend of clinical depth with ... more

Where can I find podcast stats for FLASCO OncoPod?

Rephonic provides a wide range of podcast stats for FLASCO OncoPod. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to FLASCO OncoPod and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does FLASCO OncoPod get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for FLASCO OncoPod, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for FLASCO OncoPod?

Rephonic provides comprehensive predictive audience data for FLASCO OncoPod, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does FLASCO OncoPod have?

To see how many followers or subscribers FLASCO OncoPod has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to FLASCO OncoPod?

These podcasts share a similar audience with FLASCO OncoPod:

1. MPN Pod: Stories from the Marrow
2. Blood Cancer Talks
3. The Bloodline with Blood Cancer United Podcast

How many episodes of FLASCO OncoPod are there?

FLASCO OncoPod launched 2 years ago and published 26 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact FLASCO OncoPod?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for FLASCO OncoPod?

Rephonic pulls ratings and reviews for FLASCO OncoPod from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for FLASCO OncoPod?

Rephonic provides full transcripts for episodes of FLASCO OncoPod. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on FLASCO OncoPod?

Recent guests on FLASCO OncoPod include:

1. Javier Pinilla-Ibarz
2. Robin Zon
3. Dr. Jaglal
4. Dr. Fu
5. Noman Ashraf
6. Dr. Majeed
7. Dr. Ashraf
8. Dr. Patel

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days